Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the presentation of new preclinical data for its lead drug ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...

African bishops’ conferences, largely among the church’s most conservative, pushed back against Francis' positions. After he ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Eupraxia's CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the ...

As of today, Kelun-Biotech has initiated 8 registrational clinical studies in China. MSD has initiated 12 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or ...